According to Exelixis's latest financial reports and stock price the company's current number of shares outstanding is 308,482,000. At the end of 2023 the company had 308,482,000 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2023 | 0.30 B | -4.57% |
2022 | 0.32 B | 1.79% |
2021 | 0.31 B | 2.19% |
2020 | 0.31 B | 2.11% |
2019 | 0.30 B | 1.65% |
2018 | 0.29 B | 1.14% |
2017 | 0.29 B | 2.73% |
2016 | 0.28 B | 26.69% |
2015 | 0.22 B | 16.32% |
2014 | 0.19 B | 6.05% |
2013 | 0.18 B | 10.83% |
2012 | 0.16 B | 28.81% |
2011 | 0.12 B | 18.84% |
2010 | 0.10 B | 1.24% |
2009 | 0.10 B | 1.69% |
2008 | 0.10 B | 7.1% |
2007 | 98.55 M | 17.07% |
2006 | 84.17 M | 5.83% |
2005 | 79.54 M | 10.21% |
2004 | 72.17 M | 1.66% |
2003 | 70.99 M | 25.69% |
2002 | 56.48 M | 18.29% |
2001 | 47.75 M |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 2,407,200,000 | 680.34% | ๐บ๐ธ USA |
Pfizer PFE | 5,647,000,000 | 1,730.58% | ๐บ๐ธ USA |
Amgen AMGN | 535,000,000 | 73.43% | ๐บ๐ธ USA |
Sanofi SNY | 2,507,200,000 | 712.75% | ๐ซ๐ท France |
Merck MRK | 2,554,166,667 | 727.98% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 2,057,000,000 | 566.81% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2,028,000,000 | 557.41% | ๐ฌ๐ง UK |
Curis CRIS | 5,720,789 | -98.15% | ๐บ๐ธ USA |
AVEO Oncology
AVEO | 34,618,000 | -88.78% | ๐บ๐ธ USA |